Neurofit , a company specializing in AI-based brain disease diagnosis and treatment, announced on the 8th that it had received preliminary review approval for listing from the Korea Exchange KOSDAQ Market Headquarters.
Based on this preliminary review approval, Neurofit plans to proceed with a full-scale initial public offering (IPO) by submitting a securities report and other related procedures, and Mirae Asset Securities is the lead manager for the listing.
Founded in 2016, Neurofit is a company specializing in the development of brain imaging analysis solutions and therapeutic medical devices using AI technology. Based on technology that precisely analyzes the different brain structures of each individual, it is overcoming the limitations of existing brain imaging diagnosis and treatment.
As anti-amyloid treatments such as the Alzheimer's disease treatment 'Rekembi' (active ingredient: recanemab) have recently entered the market, the importance of precise diagnosis using MRI and PET images has been emphasized, and Neurofit is providing various image analysis solutions in this field.
Its main products include 'Neurophet AQUA AD', a software that supports the prescription and monitoring of Alzheimer's disease treatment drugs, 'Neurophet AQUA', a brain neurodegeneration analysis solution, 'Neurophet SCALE PET', a PET image quantitative analysis software, 'Neurophet tES LAB', a brain imaging-based electrical stimulation treatment planning solution, and 'Neurophet innk', a transcranial electrical stimulation device.
All of these products have obtained domestic Ministry of Food and Drug Safety (MFDS) certification, and some of them have also obtained approval from major overseas regulatory agencies such as the US FDA 510(k) premarket approval, European CE certification, Japan MHLW, Singapore HSA, and Thailand TFDA.
Bin Jun-gil, Co-CEO of Neurofit, said, “With this preliminary screening approval, we can now begin preparing for an IPO in earnest,” and “We will further solidify our foundation as a comprehensive solution company that covers the entire process from diagnosis to treatment of brain diseases.”
- See more related articles
You must be logged in to post a comment.